{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Lung+Non-Small+Cell+Carcinoma&page=4", "query": { "condition": "Refractory Lung Non-Small Cell Carcinoma", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 162, "total_pages": 17, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Lung+Non-Small+Cell+Carcinoma&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Lung+Non-Small+Cell+Carcinoma&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-03T04:41:43.047Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01324479", "title": "Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "INC280", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 131, "start_date": "2012-02-29", "completion_date": "2017-07-04", "has_results": false, "last_update_posted_date": "2020-12-19", "last_synced_at": "2026-10-03T04:41:43.047Z", "location_count": 5, "location_summary": "Fayetteville, Arkansas • Chicago, Illinois • Detroit, Michigan + 2 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01324479" }, { "nct_id": "NCT07133425", "title": "A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer", "ICI-refractory" ], "interventions": [ { "name": "SAR445877", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2025-11-06", "completion_date": "2030-02-01", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-03T04:41:43.047Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07133425" }, { "nct_id": "NCT06799065", "title": "First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "Breast Cancer Recurrent", "Ovarian Cancer", "High-grade Serous Ovarian Carcinoma", "Triple Negative Breast Cancer", "sqNSCLC", "Squamous Non-small-cell Lung Cancer" ], "interventions": [ { "name": "ATX-295", "type": "DRUG" }, { "name": "ATX-295 and bevacizumab (or biosimilar)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Accent Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 218, "start_date": "2025-03-21", "completion_date": "2027-08-30", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-03T04:41:43.047Z", "location_count": 11, "location_summary": "Aurora, Colorado • Sarasota, Florida • Detroit, Michigan + 8 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06799065" }, { "nct_id": "NCT00874211", "title": "S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Lung Cancer", "Metastatic Cancer", "Multiple Myeloma", "Plasma Cell Neoplasm", "Prostate Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "assessment of therapy complications", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "120 Years", "sex": "ALL", "summary": "Up to 120 Years" }, "enrollment_count": 3571, "start_date": "2008-12", "completion_date": "2019-06", "has_results": false, "last_update_posted_date": "2019-07-05", "last_synced_at": "2026-10-03T04:41:43.047Z", "location_count": 451, "location_summary": "Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 302 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Fairbanks", "state": "Alaska" }, { "city": "Jonesboro", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00874211" }, { "nct_id": "NCT07705334", "title": "A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic Solid Tumors", "Triple Negative Breast Cancer (TNBC)", "HR+ Breast Cancer", "Colon Cancer", "Gastric Cancer", "Hepatecellular Carcinoma", "NSCLC (Advanced Non-small Cell Lung Cancer)", "Mesothelioma", "Pancreatic Carcinoma Metastatic", "Hormone Refractory Prostate Cancer", "Soft Tissue Sarcomas" ], "interventions": [ { "name": "SHY-ONC6", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SHY Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2026-06-24", "completion_date": "2028-05-15", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-03T04:41:43.047Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • Denver, Colorado • Houston, Texas + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07705334" }, { "nct_id": "NCT06999187", "title": "A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Triple Negative Breast Cancer", "HER2-negative Breast Cancer", "Non Small Cell Lung Cancer", "Cervical Cancer", "Castrate Resistant Prostate Cancer", "Pancreatic Ductal Adenocarcinoma", "Head-and-neck Squamous Cell Carcinoma", "Endometrial Cancer", "Ovarian Cancer", "Gastric Cancer", "Gastroesophageal-junction Cancer", "Urothelial Carcinoma" ], "interventions": [ { "name": "DR-0202", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dren Bio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 96, "start_date": "2025-06-03", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-01-07", "last_synced_at": "2026-10-03T04:41:43.047Z", "location_count": 10, "location_summary": "Denver, Colorado • Orlando, Florida • Sarasota, Florida + 7 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT06999187" }, { "nct_id": "NCT05856981", "title": "Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult", "Metastatic Solid Tumor", "Refractory Cancer", "CRC, Colorectal Cancer", "RCC, Clear Cell Adenocarcinoma", "NSCLC (Advanced Non-small Cell Lung Cancer)", "Endometrial Cancer" ], "interventions": [ { "name": "ADU-1805", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sairopa B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2023-04-03", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2025-12-17", "last_synced_at": "2026-10-03T04:41:43.047Z", "location_count": 4, "location_summary": "Detroit, Michigan • St Louis, Missouri • Canton, Ohio + 1 more", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Canton", "state": "Ohio" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05856981" }, { "nct_id": "NCT02489903", "title": "RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small Cell Carcinoma", "Carcinoma, Non-Small-Cell Lung", "Neuroendocrine Tumors", "Ovarian Epithelial Cancer" ], "interventions": [ { "name": "RRx-001", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Doxil", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Taxane", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EpicentRx, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 139, "start_date": "2015-06", "completion_date": "2021-12-06", "has_results": true, "last_update_posted_date": "2025-03-17", "last_synced_at": "2026-10-03T04:41:43.047Z", "location_count": 10, "location_summary": "Palo Alto, California • West Haven, Connecticut • South Bend, Indiana + 7 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "West Haven", "state": "Connecticut" }, { "city": "South Bend", "state": "Indiana" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02489903" }, { "nct_id": "NCT04691817", "title": "Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Cancer, Nonsmall Cell" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2023-07-25", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-01-07", "last_synced_at": "2026-10-03T04:41:43.047Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04691817" }, { "nct_id": "NCT00092924", "title": "Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "TRAIL-R1 mAb (TRM-1;HGS-ETR1)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Human Genome Sciences Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": "2005-03", "has_results": false, "last_update_posted_date": "2013-08-02", "last_synced_at": "2026-10-03T04:41:43.047Z", "location_count": 5, "location_summary": "Denver, Colorado • Chicago, Illinois • Durham, North Carolina + 2 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00092924" } ] }